Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganciclovir for prevention of post-transplant lymphoproliferative disease in pediatric liver transplant recipients
IRCT2013120215530N2Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ganciclovir in Post-Transplant Lymphoproliferative Disorder (PTLD) and Post-transplantation status (Post-Tx), sponsored by Shiraz University of Medical Sciences. Started Dec 2010; status: completed.
02
Drugs
ganciclovir
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)Post-transplantation status (Post-Tx)
Beyond the preview
Go deeper on IRCT2013120215530N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2013120215530N2.